Prof. Dr. Özge Gümüşay

• Brustneubildungen 13 Publikationen
  Quelle: OpenAlex / PubMed MeSHPublikationen ansehen
• Hirnneubildungen 5 Publikationen
• Nierenzellkarzinom 4 Publikationen
• Adenokarzinom 3 Publikationen
• Nierenneubildungen 3 Publikationen
• Lebertumoren 3 Publikationen
• Magenneubildungen 2 Publikationen
• Neubildungen 2 Publikationen
• Ovarialneubildungen 2 Publikationen
• Kehlkopfneubildungen 2 Publikationen
• Plattenepithelkarzinom 2 Publikationen
• Melanom 2 Publikationen

Medizinische Interessengebiete, die der Arzt im Profil der Einrichtung selbst angegeben hat. Quelle: acibadem.com.tr.

Berufserfahrung

• 2022Acıbadem Sağlık Grubuacibadem.com.tr
• 2021Stanford University Comprehensive Cancer Center, Palo Alto, Californiaacibadem.com.tr
• 2019 - 2021UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, (Meme Kanseri Onkolojisi)acibadem.com.tr
• 2014 - 2019Gaziosmanpaşa Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Uzmanıacibadem.com.tr
• 2010 - 2014Gazi Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Yan Dal Araştırma Görevlisiacibadem.com.tr
• 2006 - 2010Gazi Üniversitesi Tıp Fakültesi, İç Hastalıkları Araştırma Görevlisiacibadem.com.tr

Ausbildung

• 2023Acıbadem Üniversitesi Tıp Fakültesi / Profesör, Digeracibadem.com.tr
• 2017Gaziosmanpaşa Üniversitesi Tıp Fakültesi/ Doçent, Digeracibadem.com.tr
• 2014Gazi Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji, Üst Uzmanlıkacibadem.com.tr
• 2010Gazi Üniversitesi Tıp Fakültesi, İç Hastalıkları, Uzmanlıkacibadem.com.tr
• 2005Hacettepe Üniversitesi Tıp Fakültesi, Üniversiteacibadem.com.tr

• FachgebietMedizinische Onkologieacibadem.com.trAus der Quelle
• Abteilungsname in der QuelleMeme Kliniğiacibadem.com.trAus der Quelle
• EinrichtungAcıbadem Ataşehir Hastanesiacibadem.com.trAus der Quelle
• ArbeitsschwerpunktBrustneubildungenAus 13 Publikationen ermittelt · Modellversion —Aus der Quelle
• Publikationen69 PublikationenOpenAlexAus der Quelle
• Letzte Synchronisierung4. November 2026 20:44https://www.acibadem.com.tr/doktor/ozge-gumusay/acibadem.com.tr

1. Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer

   Current Treatment Options in Oncology, 2026

   DOI 10.1007/s11864-026-01391-3 PMID 41999452 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

2. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

   Immunotherapy, 2026

   DOI 10.1080/1750743x.2026.2662201 PMID 42011533 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

3. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

   Turkish Journal of Clinics and Laboratory, 2025

   DOI 10.18663/tjcl.1639022 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

4. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

   Clinical Breast Cancer, 2025

   DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

5. Abstract P4-11-03: Prediciting high risk hormone receptor (HR) positive Her-2 negative early breast cancer (BC) by artificial intelligence (AI) algorithms

   Clinical Cancer Research, 2025

   DOI 10.1158/1557-3265.sabcs24-p4-11-03 Quelle: OpenAlex

6. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

   Journal of Chemotherapy, 2024

   DOI 10.1080/1120009x.2024.2366683 PMID 38904164 1 Zitation (Europe PMC) Quelle: OpenAlex

7. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

   Clinical Genitourinary Cancer, 2024

   DOI 10.1016/j.clgc.2024.102077 PMID 38626660 2 Zitationen (Europe PMC) Quelle: OpenAlex

8. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

   BMC Cancer, 2024

   DOI 10.1186/s12885-024-13357-5 PMID 39736618 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

9. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

   Journal of Cancer Research and Clinical Oncology, 2023

   DOI 10.1007/s00432-023-04766-3 PMID 37067546 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

10. Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

    CA A Cancer Journal for Clinicians, 2023

    DOI 10.3322/caac.21777 PMID 36939293 182 Zitationen (Europe PMC) Quelle: OpenAlex